Anti-Cancer

Ceritinib (SPEXIB HGC) 150MG 30 Tablet

$525.00

SPEXIB HGC Tablet offers a valuable treatment option for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC), providing an effective and targeted therapy to help manage this challenging malignancy.

Quantity

Ceritinib (SPEXIB HGC) 150MG 30 Tablet quantity

Add to cart

Tag:

Ceritinib (SPEXIB HGC)

Description

SPEXIB HGC Tablet contains Ceritinib in a strength of 150mg, serving as a medication primarily prescribed for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with ALK-positive metastatic NSCLC.

Key Features:

• Non-Small Cell Lung Cancer (NSCLC) Treatment: SPEXIB HGC Tablet is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in patients with ALK (anaplastic lymphoma kinase) gene rearrangement.
• Ceritinib Mechanism of Action: Ceritinib, the active ingredient in SPEXIB HGC, is a tyrosine kinase inhibitor that targets the ALK protein, which is often mutated or overexpressed in certain types of NSCLC. By inhibiting ALK activity, Ceritinib helps suppress tumor growth and progression.
• ALK-Positive NSCLC: SPEXIB HGC is specifically indicated for use in patients with ALK-positive metastatic NSCLC, a subtype of NSCLC associated with a specific genetic mutation that drives tumor growth.
• Fixed-Dose Tablet: SPEXIB HGC Tablet contains a fixed dose of Ceritinib (150mg) in each tablet, simplifying dosing and ensuring consistent medication delivery.
• Oral Administration: Administered orally, usually once daily with food, SPEXIB HGC Tablet offers convenient dosing for patients with NSCLC, allowing them to take their medication at home.
• Clinical Efficacy: Clinical studies have demonstrated the efficacy of Ceritinib in achieving tumor responses and prolonging progression-free survival in patients with ALK-positive metastatic NSCLC.
• Potential Adverse Effects: Common side effects of SPEXIB HGC may include nausea, diarrhea, vomiting, fatigue, and elevated liver enzymes. Patients should be monitored closely for adverse reactions and managed accordingly.
• Individualized Treatment Approach: The selection of SPEXIB HGC as a treatment option for NSCLC should be based on factors such as ALK mutation status, prior treatment history, presence of comorbidities, and patient’s overall health status.